et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518–27. , ,
et al. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat 2008; 110: 273–81. , ,
et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial–mesenchymal transition. Oncogene 2008; 27: 323–31. , ,
et al. CD151 dyanmicx in carcinoma–stroma interaction: integrin expression, adhesion strength and proteolytic activity. Lab Invest 2007; 87: 882–92. , ,
et al. Prognostic impact of syndecan-1 expression in invasive ductal carcinomas. Br J Cancer 2008; 98: 1993–8. , ,
et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008; 68: 9087–95. , ,
et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 1998; 49: 195–208. , ,
et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol 2002; 15: 502–16. , ,
et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 2001; 39: 416–25. , ,
et al. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer 2005; 41: 2093–101. , ,
et al. Significance of basic fibroblast growth factor and fibroblast growth factor receptor protein expression in the formation of fibrotic focus in invasive ductal carcinoma of the breast. Jpn J Cancer Res 1997; 88: 877–85. , ,
et al. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 2000; 156: 1701–10. , ,
et al. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol 2001; 14: 325–37. , ,
p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81–137. , .
et al. p53 mutations in human cancers. Science 1991; 253: 49–53. , ,
Cell-cycle check-points and cancer. Nature 2004; 432: 316–23. , .
et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinoma. Nat Genet 2002; 32: 355–7. , ,
et al. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2006; 123: 1001–11. , ,
Under pressure: stromal fibroblasts change their ways. Cell 2005; 123: 985–7. , .
et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implication for tumorigenesis. Cancer Res 2000; 60: 2562–6. , ,
et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. New Engl J Med 2007; 357: 2543–51. , ,
TNM Classification of Malignant Tumors, 6th edn. Geneva: Wiley-Liss, 2002. , , eds.
Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359–77. , .
et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 eastern cooperative oncology group patients. J Clin Oncol 1993; 11: 1929–35. , ,
et al. A proposal for a new histological classification scheme for predicting short-term tumor recurrence and death in patients with invasive ductal carcinoma of the breast. Jpn J Cancer Res 1998; 89: 1358–73. , ,
et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155–68. , ,
et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–81. , ,
et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004; 17: 1545–54. , ,
et al. Estrogen- and progesterone-receptor status in ECOG2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008; 26: 2473–81. , ,
et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200–6. , ,
et al. American Scociety of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18–43. , ,
Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81. , .
et al. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 2005; 65: 1627–30. , ,
et al. Molecular characterization of the tumor microenviroment in breast cancer. Cancer Cell 2004; 6: 17–32. , ,
et al. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 2007; 9: R19. , ,
et al. Breast-cancer stromal cells with TP53 mutations. New Engl J Med 2008; 10: 1634–5. , ,
et al. Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: a prospective study. Hum Pathol 2008; 39: 681–93. , ,